Business

Know the Business

Figures converted from CNY at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Yatsen is a sub-scale Chinese DTC beauty group whose flagship Perfect Diary made it the poster child of "data-driven" mass color cosmetics in 2020, and whose subsequent five years are a case study in what happens when a paid-traffic engine outruns brand equity. The business has just clawed back to non-GAAP breakeven (FY2025) by leaning on acquired skincare brands — Galénic, DR.WU and Eve Lom — and the bull case now hinges on whether premium skincare can pull the company off the Douyin treadmill before the cash buffer runs out.

How This Business Actually Works

Yatsen rents traffic from Tmall, Douyin and Xiaohongshu, converts it into a high-margin sale, and tries to keep the customer through Weixin "private domain" beauty advisors and an offline experience-store network. Manufacturing is outsourced to ODM/OEM partners (Cosmax, Intercos, Kolmar), so the income statement is dominated by two line items: gross margin (driven by mix) and selling & marketing (driven by traffic price).

The waterfall is the whole story: gross profit of $78 per $100 of revenue is world-class, but ~$65 of that goes straight back out to digital platforms and KOLs as selling & marketing (S&M was 64.8% of revenue in Q4 2025, up from 60.1% in Q4 2024 because of Double 11 traffic inflation). Fulfillment, G&A and R&D consume the remaining 12-13 points. The unit therefore breaks even, plus or minus a percent, almost entirely as a function of S&M intensity. A single point of S&M leverage is a point of operating margin.

That mechanic is why management keeps repeating two priorities — mix-shift to skincare (which sustains higher LTV and lower discount intensity) and "stricter ROI discipline" on Douyin spend. It is also why the Color Cosmetics business is being managed for cash, not growth: skincare grew 63.5% in FY2025 while color cosmetics inched up 1.9%. The economic engine here is not "sell more lipsticks" — it is "earn enough customer retention on a serum to stop paying KOLs to find the same shopper again."

The Playing Field

Yatsen sits at the worst possible spot of the global beauty peer set: highest gross margin in the group, lowest operating margin, smallest scale. Local rival Proya Cosmetics — not in the table because it lists in Shenzhen — has quietly become China's #1 domestic cosmetics company by doing the opposite of Yatsen: focus on a single skincare-led brand, run lean, and compound profitably. That is the comparison that matters most strategically, even if the public-market peer set is Western.

YSG figures converted from CNY at the 2025-12-31 rate of ¥1 = US$0.14284. Other peers report natively in USD. Ratios are unitless.

The chart isolates the diagnostic: every other peer earns a positive operating margin despite lower gross margin, while Yatsen converts the highest gross margin in the room into the worst operating outcome. ELF runs the same DTC playbook with similar gross margin and clears double-digit operating margins — proof the model can work, but only with brand pull strong enough to avoid the worst paid-traffic auctions. Ulta is structurally different (a retailer, with 39% gross margin but 12.5% operating margin and 44% ROE) — included because it is the asset of choice when investors want exposure to U.S. beauty without single-brand risk. Estée Lauder is the cautionary tale of even prestige-brand pricing power being insufficient when China travel retail rolls over.

What "good" looks like in this industry is neither the highest gross margin nor the largest brand portfolio — it is the lowest paid-traffic dependence per dollar of brand sales. ELF, Proya and (historically) Estée Lauder all clear that bar in different ways. Yatsen does not, yet.

Is This Business Cyclical?

Yatsen's cycle is not the macro consumer cycle (the lipstick effect actually held during Chinese lockdowns); it is a platform-mix cycle. The 2020-2025 chart is one violent swing from a Tmall-and-KOL boom to a Douyin-cost shock and back to a tentative skincare-led recovery. Cycles in this business are about which platform is monetising your traffic, not about consumer wallet share.

The 2020-2022 swing is the entire risk model in microcosm. Yatsen IPO'd at the top of a once-in-a-decade c-beauty bubble — Perfect Diary's Tmall-plus-KOL formula was effectively a regulatory arbitrage on Alibaba's traffic prices — and discovered in 2022 that the same formula on Douyin costs roughly twice as much per acquired customer. Revenue fell 35% in a single year, but more revealing is what fell with it: gross margin actually went up (from 64% in 2020 to 78% in 2025) because management raised price and shut down the loss-making mass-market arm. The cycle hits selling & marketing intensity, not pricing power.

The recovery is real but unfinished. China beauty retail grew 5.1% in FY2025 (8.2% in Q4) per the National Bureau of Statistics; Yatsen's 26.7% top-line growth was largely skincare share-gain on top of that tide. The unanswered question — and the next downturn risk — is what happens when Douyin's CPC environment tightens again, as it did in late 2025 around Double 11 (S&M jumped to 64.8% of revenue). The cycle has one more turn left in it before the model is proven.

The Metrics That Actually Matter

Forget P/E (negative), forget P/B (book value is mostly goodwill already impaired, and accumulated deficit is $1.16B). The five numbers that determine whether the equity is a zero or a multi-bagger are below.

Why these five and not the usual ratios:

Skincare share of revenue. Color cosmetics in China is a paid-traffic commodity (no brand pricing power, KOL-driven, Gen-Z fashion cycles); skincare is a habit category with repeat purchase and clinical defensibility. The 33.5% → 53% migration is the single most important value-creation lever, far more than any margin line.

Gross margin. A direct readout of mix shift and discount discipline. A break above 80% would signal the premium-skincare thesis is winning the basket; any fall below 75% means promotion is back.

S&M as % of revenue. The only metric that actually moves the needle on operating margin. Watch it quarter-by-quarter, not annually — the Q4 2025 spike to 64.8% is the warning signal of the moment.

Non-GAAP operating margin. GAAP is dominated by goodwill impairments and SBC; non-GAAP captures whether the underlying engine makes money. FY2025's −2.0% is within striking distance of zero for the first time since 2019.

Cash + short-term investments. With no debt, this is the runway clock. $151M at end-2025 against $13.5M of FY2025 operating cash burn is roughly 11 years of runway at the current rate — but the March 2026 announcement of a US$120M convertible from Trustar Capital (and CEO Huang co-investing personally) suggests management wants firepower for M&A and overseas expansion, not just survival cash.

What I'd Tell a Young Analyst

This is not a beauty company; it is a Douyin-and-Xiaohongshu media-arbitrage business with a cosmetics inventory hedge attached. Underwrite that — not the brand portfolio.

The bull thesis hinges on one specific testable claim: that skincare repeat-purchase and brand pull will let S&M / revenue drift down through the 50s while gross margin holds above 75%. If that happens, operating margin compounds quickly because there is almost no other cost line to fix. If S&M stays stuck above 60%, this is a permanent breakeven asset trading at 0.06x sales because that is what permanent breakeven assets are worth.

Three things to watch over the next four quarters: (1) Skincare share — does it cross 60% in FY2026 as DR.WU and Galénic continue compounding, (2) Q1-Q3 S&M intensity — does Q4 prove to be Double-11-festive noise or the new run-rate, and (3) what management does with the US$120M Trustar money — accretive skincare M&A would extend the thesis; another vanity premium-brand acquisition like Eve Lom ($55M of impairment in 2024) would tell you the lessons of 2021 were not learned.

Two things the market is probably wrong about. It treats this as a dying mass color-cosmetics brand (it isn't anymore — color is now a managed-decline cash unit and skincare is over half the revenue), and it ignores the option value of a founder-led, debt-free, $150M-cash-rich balance sheet at a $268M market cap when a Chinese skincare consolidation cycle appears to be starting. The bear thesis — that beauty in China is a winner-take-all platform game and Proya already won — is also defensible. Pick a side based on the next two prints, not on the brand story.